Christopher Raymond
Stock Analyst
(3.49)
# 3,966
Out of 4,648 analysts
120
Total ratings
53.4%
Success rate
3.05%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $1,242 → $1,195 | $828.84 | +44.18% | 6 | Nov 1, 2024 | |
| BHVN Biohaven | Maintains: Overweight | $66 → $76 | $50.10 | +51.70% | 7 | Sep 23, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $107 → $122 | $66.01 | +84.82% | 14 | Sep 5, 2024 | |
| IOBT IO Biotech | Maintains: Overweight | $10 | $1.19 | +740.34% | 2 | Sep 3, 2024 | |
| ABBV AbbVie | Maintains: Overweight | $196 → $209 | $200.53 | +4.23% | 10 | Aug 23, 2024 | |
| TYRA Tyra Biosciences | Initiates: Overweight | $33 | $16.42 | +100.97% | 1 | Aug 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $500 → $535 | $472.80 | +13.16% | 7 | Aug 2, 2024 | |
| BIIB Biogen | Maintains: Overweight | $335 → $313 | $173.52 | +80.38% | 18 | Jul 12, 2024 | |
| TSHA Taysha Gene Therapies | Maintains: Overweight | $9 → $7 | $1.34 | +422.39% | 2 | Jul 1, 2024 | |
| ARDX Ardelyx | Maintains: Overweight | $15 | $5.89 | +154.67% | 6 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $78 → $104 | $91.88 | +13.19% | 3 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $10.55 | +298.10% | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $46.84 | -3.93% | 1 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $21 | $1.49 | +1,309.40% | 5 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $27 → $1.5 | $0.89 | +69.11% | 2 | Dec 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $5 | $0.93 | +435.91% | 3 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $130 | $51.06 | +154.60% | 4 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $11.87 | +85.34% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.85 | +116.22% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $25 | $5.96 | +319.46% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $316.91 | -9.12% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $44.83 | -8.54% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $46.30 | -39.52% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $89.53 | -55.32% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.66 | +1,490.11% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $2.17 | +1,282.49% | 1 | Jun 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $5.52 | +1,639.13% | 2 | Mar 13, 2020 |
Regeneron Pharmaceuticals
Nov 1, 2024
Maintains: Overweight
Price Target: $1,242 → $1,195
Current: $828.84
Upside: +44.18%
Biohaven
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $50.10
Upside: +51.70%
BioMarin Pharmaceutical
Sep 5, 2024
Maintains: Overweight
Price Target: $107 → $122
Current: $66.01
Upside: +84.82%
IO Biotech
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $1.19
Upside: +740.34%
AbbVie
Aug 23, 2024
Maintains: Overweight
Price Target: $196 → $209
Current: $200.53
Upside: +4.23%
Tyra Biosciences
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $16.42
Upside: +100.97%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Overweight
Price Target: $500 → $535
Current: $472.80
Upside: +13.16%
Biogen
Jul 12, 2024
Maintains: Overweight
Price Target: $335 → $313
Current: $173.52
Upside: +80.38%
Taysha Gene Therapies
Jul 1, 2024
Maintains: Overweight
Price Target: $9 → $7
Current: $1.34
Upside: +422.39%
Ardelyx
May 24, 2024
Maintains: Overweight
Price Target: $15
Current: $5.89
Upside: +154.67%
May 3, 2024
Maintains: Neutral
Price Target: $78 → $104
Current: $91.88
Upside: +13.19%
Apr 29, 2024
Initiates: Overweight
Price Target: $42
Current: $10.55
Upside: +298.10%
Apr 2, 2024
Initiates: Overweight
Price Target: $45
Current: $46.84
Upside: -3.93%
Mar 8, 2024
Maintains: Overweight
Price Target: $11 → $21
Current: $1.49
Upside: +1,309.40%
Dec 22, 2023
Downgrades: Neutral
Price Target: $27 → $1.5
Current: $0.89
Upside: +69.11%
Nov 3, 2023
Maintains: Overweight
Price Target: $7 → $5
Current: $0.93
Upside: +435.91%
Oct 25, 2023
Maintains: Overweight
Price Target: $135 → $130
Current: $51.06
Upside: +154.60%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $11.87
Upside: +85.34%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.85
Upside: +116.22%
May 12, 2023
Maintains: Overweight
Price Target: $26 → $25
Current: $5.96
Upside: +319.46%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $316.91
Upside: -9.12%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $44.83
Upside: -8.54%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $46.30
Upside: -39.52%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $89.53
Upside: -55.32%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.66
Upside: +1,490.11%
Jun 15, 2021
Initiates: Overweight
Price Target: $30
Current: $2.17
Upside: +1,282.49%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $5.52
Upside: +1,639.13%